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Since the discovery of nicotinamide phosphoribosyltransferase
(NAMPT) as a pre-B cell-enhancing factor in 1994 by Samal et al. [1],
many papers have described the pleiotropic function of this enzyme.
A vital role of NAMPT in mammalian cells was attributed to its activ-
ity as a rate-limiting enzyme in the biosynthesis of nicotinamide ade-
nine dinucleotide (NAD) from nicotinamide, and was supported by
its widespread tissue distribution and by the embryonic lethality of
total NAMPT knock-out mice [2].
It has been shown that tumours require increased levels of ener-
getic molecules. Metabolic rewiring is now considered one of the
hallmarks of tumours, sustaining the production of cellular energy
[ie, adenosine triphosphate (ATP)], and their growth and invasive
capacities [3]. The redox co-factor NAD, is fundamental in several
metabolic reactions, and as a substrate for different NAD-consuming
enzymes [eg, poly-ADP-ribose polymerases (PARPs) and sirtuins],
involved in many cellular processes, including DNA repair and epige-
netic regulation of gene expression [4]. A common strategy that sev-
eral tumour types adopt to sustain NAD production is to over-
express NAMPT, regulated at the transcriptional level [5]. This finding
has led to the design of numerous NAMPT inhibitors (NAMPTi) in the
context of cancer therapy. Despite significant results in vitro and in
vivo, phase I clinical trials with the first NAMPTi (ie, FK866 and
GMX1778) in haematological or solid malignancies, showed no
objective tumour remission, and toxicity. Besides the pharmacologi-
cal properties of these drugs and their potential toxicity, one of the
main aspects leading to the partial failure of NAMPTi treatment was
due to the concomitant expression of others NAD-biosynthetic
enzymes that can overcome NAMPT inhibition. It is now clear in the
field that it is necessary to select tumours uniquely addicted to
NAMPT activity in the generation of NAD. Novel NAMPTi are cur-
rently in pre-clinical and phase I-II clinical trials, highlighting an
intense pharmacological effort to target this enzyme [6].E-mail address: valentina.audrito@unito.it
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role of NAMPT as an intracellular NAD-biosynthetic enzyme. How-
ever, NAMPT has emerged as a mediator of inflammation with impor-
tant, context-dependent, extracellular functions [7]. Increased
extracellular (e)NAMPT levels are reported in conditions of acute or
chronic inflammation, including tumours, correlating with worse
prognosis and increased tumour aggressiveness as reviewed in [7].
Moreover, eNAMPT acts as a cytokine that modulates the immune
response, and as an adipokine (also known as visfatin) that plays a
critical role in metabolic diseases [5]. In 2015, Garcia and colleagues
identified Toll-like receptor 4 (TLR4) as an eNAMPT receptor, there-
fore adding the enzyme to a number of damage-associated molecular
patterns (DAMPs) molecules: “danger” signals activating this recep-
tor [7,8]. Much unknown and incomplete information remains to be
addressed regarding the nature of eNAMPT’s post-translational modi-
fications, its mechanism of secretion, and its enzymatic activity in the
extracellular space. However, a proposed strategy of blocking
eNAMPT is emerging. This is the focus of the paper by Sun et al. pub-
lished in this issue of EBioMedicine [9]. The tumour model that the
authors used to verify the role of eNAMPT as a biomarker and thera-
peutic target was invasive prostate cancer (PCa). Over-expression of
intracellular NAMPT protein was previously demonstrated in 2011
by Wang et al. They demonstrated that inhibition of NAMPT signifi-
cantly suppresses cell growth in culture, soft agar colony formation,
cell invasion, and growth of xenografted prostate cancer cells in mice
[10]. However, the role of NAMPT in PCa is largely unexplored. Sun
et al. added novel insight about i) the regulation of NAMPT expres-
sion in PCa via hypoxia-inducible factor 1-alpha/beta (HIF-1a/b), ii)
the presence of higher eNAMPT protein in plasma from PCa patients
compared to healthy donors, iii) the activity of eNAMPT in supporting
the invasive features of PCa, and iv) the tumour blocking activity of
anti-eNAMPT neutralizing antibody in a pre-clinical in vivo model of
PCa invasion. The regulation of NAMPT transcriptional expression and
the activity of eNAMPT in promoting a tumour invasive phenotype
are known in a variety of tumour types. However, two novel and sig-
nificant findings emerged from this paper.
The first one is that the elevated levels of eNAMPT in PCa have a
predictive value for PCa diagnosis and correlate with aggressive PCa,
suggesting that this protein could be consider a novel biomarker in
PCa. This finding opens up the possibility of a clinically-utilized
eNAMPT biomarker screen to assess PCa risk. To-date, prostate-spe-
cific antigen (PSA) levels are considered the only PCa biomarker to
discriminate between prostate benign hyperplasia or inflammationder the CC BY license (http://creativecommons.org/licenses/by/4.0/)
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from high false-positive results, high variability, and fails to correlate
with PCa aggressiveness. On the contrary, at least in the cohort ana-
lyzed in the paper, high (>30 ng/ml) eNAMPT levels are associated
with aggressive and invasive PCa. Of course, future studies to confirm
these results are needed. However, this paper proposes, for the first
time, eNAMPT as a biomarker in PCa patients, to be used alone or in
combination with PSA.
The second important and translational message is the therapeu-
tic potential of eNAMPT neutralization, using a specific blocking anti-
body, to prevent the invasiveness and metastasis of PCa. The authors
studied the capacity of PCa cells to invade the inferior diaphragmatic
muscle in vivo, demonstrating that mice treated with polyclonal neu-
tralizing anti-eNAMPT antibody had fewer and smaller colonies on
the inferior diaphragm, confirming an inhibition of invasive capacity.
The general idea of targeting eNAMPT in tumours is increasing, to
counteract the extracellular functions of this protein, mainly linked
to the activation of TLR4 and modulation of immune responses. It
would be very interesting to address whether the block of eNAMPT
acts on the PCa tumour as well as on the PCa tumour microenviron-
ment. This approach might not be restricted to PCa, and perhaps a
combination of pharmacological NAMPTi and eNAMPT blocking anti-
body to affect the dual roles of this enzyme/cytokine, will be a suc-
cessful approach to halt tumour progression and instigate a less
supportive tumour microenvironment.
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